The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease

Basit Öğe Kaydı
dc.contributor.authorOzcan, Seyda Gul
dc.contributor.authorEren, Necmi
dc.contributor.authorDincer, Mevlut Tamer
dc.contributor.authorAtli, Zeynep
dc.contributor.authorBolayirli, Murat
dc.contributor.authorErgul, Metin
dc.contributor.authorOzer, Hakan
dc.date.accessioned2026-04-25T14:20:17Z
dc.date.available2026-04-25T14:20:17Z
dc.date.issued2025
dc.departmentSinop Üniversitesi
dc.description.abstractBackground Fabry disease is a rare lysosomal storage disorder. The genotypic and phenotypic heterogeneity of the disease complicates the prediction of disease activity. This study aimed to evaluate the association between multiple plasma biomarkers and disease activity in Fabry disease. Methods A cross-sectional analysis was conducted involving 87 Fabry patients, 46 chronic kidney disease (CKD) patients, and 41 healthy controls. Plasma levels of KIM-1, MCP-1, YKL-40, TNFR-1, TNFR-2, and cystatin-C were measured using ELISA. eGFR was calculated using creatinine and creatinine-cystatin C-based CKD-EPI formulas. Fabry patients on renal replacement therapy were analyzed as a subgroup. Primary analyses focused on 62 Fabry patients receiving enzyme replacement therapy. Results Although eGFR (cr) did not differ significantly between Fabry patients and healthy controls, eGFR(cr-cys) was significantly lower in Fabry patients. After adjusting for age, gender, and BMI, MCP-1 and TNFR-2 levels were significantly lower in Fabry patients than in CKD patients. Among Fabry patients, those with renal involvement, had significantly higher MCP-1 levels than those without. While KIM-1 and YKL-40 did not differ significantly between groups, both were significantly elevated in patients with Lyso-Gb3 > 4 ng/mL and positively correlated with Lyso-Gb3. Conclusion MCP-1, TNFR-2, YKL-40, and cystatin C may serve as potential biomarkers for different aspects of Fabry disease activity. Further investigation into the associated pathogenic pathways may support the development of novel diagnostic tools or targeted therapies.
dc.description.sponsorshipIstanbul University-Cerrahpasa Scientific Research Projects department [36251, TTU-2022-36251]
dc.description.sponsorshipWe conducted the study with the support of Istanbul University-Cerrahpasa Scientific Research Projects department (Project number: 36251, Project code: TTU-2022-36251).
dc.identifier.doi10.1186/s12882-025-04189-x
dc.identifier.issn1471-2369
dc.identifier.issue1
dc.identifier.pmid40420032
dc.identifier.scopus2-s2.0-105006447493
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12882-025-04189-x
dc.identifier.urihttps://hdl.handle.net/11486/8482
dc.identifier.volume26
dc.identifier.wosWOS:001495992400004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260420
dc.subjectFabry disease
dc.subjectPlasma biomarkers
dc.subjectGenetic kidney disease
dc.titleThe relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu